162 results on '"Kajiwara E"'
Search Results
2. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure
3. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia
4. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study
5. Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort
6. Efficacy and safety of direct-acting antivirals for 1,961 Japanese chronic hepatitis C patients – Real Word Data from a multicenter cohort
7. Effectiveness and safety of sofosbuvir-based regimens for Japanese patients with hepatitis C virus genotype 1b or 2 infection: real life experience from a multicenter cohort
8. Factors that influence the improvement of serum albumin during interferon-free sofosbuvir/ledipasvir therapy for Japanese patients with chronic hepatitis C virus infection
9. The Safety and Efficacy of Direct-Acting Antiviral Treatment for Patients with Genotype 1 Chronic Hepatitis C and Renal Impairment
10. FRI-418 - Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort
11. THU-350 - Efficacy and safety of direct-acting antivirals for 1,961 Japanese chronic hepatitis C patients – Real Word Data from a multicenter cohort
12. P0845 : Comparative study on the effectiveness of simeprevir or telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1b infection
13. P0833 : Simeprevir- and telaprevir-based triple therapies for genotype 1b chronic hepatitis C patients aged 70 and over in a multicentre cohort study
14. P1108 EFFICACY AND TOLERABILITY OF TELAPREVIR-BASED TRIPLE THERAPY FOR ADVANCED FIBROSIS STAGE CHRONIC HEPATITIS C PATIENTS: RESULTS OF THE KYUSHU UNIVERSITY LIVER DISEASE STUDY GROUP
15. P1103 IMPACT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL ON RESPONSE TO TELAPREVIR-BASED TRIPLE THERAPY FOR CHRONIC HEPATITIS C PATIENTS
16. P1170 VIROLOGICAL RESPONSE AT WEEK 6 OF TELAPREVIR-BASED TRIPLE THERAPY IS THE MOST EFFECTIVE PREDICTOR OF CHRONIC HEPATITIS C TREATMENT OUTCOME
17. SAT-225 - The Safety and Efficacy of Direct-Acting Antiviral Treatment for Patients with Genotype 1 Chronic Hepatitis C and Renal Impairment
18. 886 IMPACT OF THE VIRAL KINETICS OF CHRONIC HEPATITIS C PATIENTS TREATED WITH TELAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON a2b AND RIBAVIRIN
19. 510 DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS WHO ACHIEVE SUSTAINED VIROLOGICAL RESPONSE TO INTERFERON THERAPY
20. 1146 AGE IS THE MOST IMPORTANT RISK OF HEPATOCELLULAR CARCINOMA OF SUSTAINED VIROLOGICAL RESPONDERS TO TREATMENT FOR CHRONIC HEPATITIS C
21. 1145 IMPACT OF PEGYLATED INTERFERON a2B PLUS RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C PATIENTS WITH HISTORY OF HEPATOCELLULAR CARCINOMA
22. 1144 COMPLETE HEPATITIS C VIRUS ELIMINATION DURING PEGYLATED INTERFERON a2B AND RIBAVIRIN TREATMENT REDUCES THE RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA
23. A compact laparoscope type radiation source for the pin-point cancer treatment using a femtosecond laser
24. Development of a localized x-ray source for the pin-point treatment of cancers using femtosecond laser
25. Development of a Localized X-ray Source for the Pin-Point Treatment of Cancers using Femt-second Laser
26. Efficacy of prolonged treatment following combination with ribavirin and interferon for chronic hepatitis type C: A pilot study
27. Body surface area is an independent factor contributing to the effects of lamivudine treatment
28. Development of a localized x-ray source for the pin-point treatment of cancers using femtosecond laser.
29. Ileal varices associated with recurrent bleeding in a patient with liver cirrhosis.
30. A compact laparoscope type radiation source for the pin-point cancer treatment using a femtosecond laser
31. Prevalence and long-term prognosis of mild hypertensives and hypertensives in a Japanese community, Hisayama.
32. Transient cerebral ischemic attacks in a Japanese community, Hisayama, Japan.
33. Role of bursin in the development of B lymphocytes in chicken embryonic Bursa of Fabricius
34. A hole in the T-cell repertoire induced after retroviral infection of immunocompetent adult mice
35. P-303 Mechanism of the changes of platelet counts during interferon therapy in HCV-positive chronic liver disease (CLD)
36. Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.
37. Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
38. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
39. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
40. Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection.
41. Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.
42. Dissolution Profiles of Generic Products in Dissolution Media Defined by Japanese Guidelines for Bioequivalence Studies.
43. Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C.
44. Impact of Quality by Design Development on the Review Period of New Drug Approval and Product Quality in Japan.
45. Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.
46. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
47. Effect of interprofessional education on oral assessment performance of nursing students.
48. Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis.
49. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
50. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.